Request a Quote |

Announcement regarding press comment

Further to today's article in the Financial Times the board of Cyprotex would like to confirm that, as published in its prospectus dated 12 February 2002, Gilbert Eliott, acting as broker to the Company, raised £6.5 million (before expenses) from institutional and other investors. Dresdner Kleinwort Wasserstein Securities Limited was a significant investor under this placing however at that time the Company had no knowledge that this investment was related to any spread betting. Paul Davidson, whilst a major shareholder, is not a director of Cyprotex.

The directors of the Company are pleased with progress to date and following flotation it has incorporated a subsidiary company in the United States and Cyprotex announced on 7 March 2002 that it had won a significant rolling contract with a UK biotechnology company.

- Ends -

Enquiries:

Phil Adams

Altium Capital Limited
Tel: +44 (0) 161 831 9133

philip.adams@altiumcapital-m.co.uk
www.altiumcapital.com

Henry Harrison-Topham
Tel: +44 (0) 20 7444 4141

Bankside Consultants Limited

henry.ht@bankside.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Close